ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
$0.028
arrow_upward
+0.36%(+0.00010) 1D
Oct 8, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
$0.02
High
$0.03
Low
$0.02
Mkt. cap
7.17M
Avg. vol.
210.93K
Volume
50.88K
52-wk high
$0.28
52-wk low
$0.00
Beta
0.75
Shares outstanding
265.05M
No. of employees
272
Open
$0.02
High
$0.03
Low
$0.02
Mkt. cap
7.17M
Avg. vol.
210.93K
Volume
50.88K
52-wk high
$0.28
52-wk low
$0.00
Beta
0.75
Shares outstanding
265.05M
No. of employees
272
News stories
From web sources and news partners
TipRanks
·
23 minutes ago
Closing Bell Movers: Telecom stocks fall on SpaceX spectrum license
MarketWatch
·
4 hours ago
S&P Global Inc. stock underperforms Thursday when compared to competitors despite daily gains
TradingView
·
3 hours ago
Analyst Sets Stark S&P 500 Target For 2027
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR